DRTX News Alert Durata Therapeutics Inc (DRTX) 24.16 12/17/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Durata Therapeutics Inc (DRTX) 24.16 $DRTX

Merger Arbitrage Mondays - November 24, 2014
Asif Suria - at Seeking Alpha - Mon Nov 24, 4:38AM CST
Merger Activity decreased last week with five new mergers announced and five deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
DRTX: 24.16 (+0.41), ACT: 256.52 (-6.48), MONT: 22.59 (+0.26), CHYR: 2.80 (unch), TDY: 97.36 (-0.90), QRE: 14.35 (-0.50), HAL: 38.11 (+0.29), BBEP: 7.65 (+0.70), AGN: 205.75 (-3.26), LPDX: 5.24 (-0.01), BOLT: 21.99 (+0.01), VYFC: 19.72 (-0.13), BNCN: 16.41 (+0.03), LH: 101.90 (+0.54), OPLK: 24.20 (+0.01), BHI: 55.15 (+0.22)

ArQule (ARQL) Shows Strength: Stock Adds 6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:39AM CST
ArQule Inc. (ARQL) was a big mover last session, as its shares rose nearly 6% on the day.
DRTX: 24.16 (+0.41), LCI: 42.70 (-1.35), ARQL: 1.16 (unch), BIOD: 1.30 (-0.02)

Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 7:51AM CST
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as its shares rose over 6% on the day.
DRTX: 24.16 (+0.41), LCI: 42.70 (-1.35), ESPR: 34.52 (-0.48), BIOD: 1.30 (-0.02)

PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics
PR Newswire - Tue Nov 18, 6:00AM CST
PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that in connection with the acquisition of Durata Therapeutics, Inc. by Actavis, PDL has received approximately $42.7 million in connection with the termination of PDL's credit agreement with Durata, which included repayment of the full principal amount outstanding of $40 million, accrued interest, and prepayment and change of control premiums. In October 2013, PDL entered into a structured financing transaction with Durata in which PDL agreed to provide Durata with up to $70 million of debt financing with a five year term and in turn would receive interest on the principal amount outstanding and a security interest in substantially all of Durata's assets.
DRTX: 24.16 (+0.41), PDLI: 7.32 (-0.07)


Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
DRTX: 24.16 (+0.41), AGN: 205.75 (-3.26), ACT: 256.52 (-6.48), VRX: 136.92 (-1.24), MRK: 56.80 (-0.15), VRX.TO: 159.38 (-1.78)

Actavis Rumored to be Close to Acquiring Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:00AM CST
As per market rumors, Actavis (ACT) is closing in on a deal to acquire Allergan (AGN) for over $65.5 billion.
DRTX: 24.16 (+0.41), ZTS: 40.85 (-0.89), AGN: 205.75 (-3.26), ACT: 256.52 (-6.48), VRX: 136.92 (-1.24)

Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer
PR Newswire - Mon Nov 17, 7:00AM CST
Actavis plc (NYSE: ACT) today announced that it has successfully completed its tender offer to purchase all outstanding shares of Durata Therapeutics, Inc. (NASDAQ: DRTX), an innovative pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. As previously announced, Actavis offered to purchase all outstanding shares of Durata for $23.00 per share in cash, or approximately $675 million in the aggregate, and one contingent value right (CVR) per share, entitling the holder to receive additional cash payments of up to $5.00 per CVR if certain regulatory or commercial milestones related to Durata's lead product DALVANCETM are achieved.
DRTX: 24.16 (+0.41), ACT: 256.52 (-6.48)

5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 24.16 (+0.41), AGN: 205.75 (-3.26), ACT: 256.52 (-6.48), IRWD: 13.80 (+0.10), CBST: 96.73 (+0.42), PFE: 30.67 (-0.19)

Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 24.16 (+0.41), AGN: 205.75 (-3.26), ACT: 256.52 (-6.48), VRX: 136.92 (-1.24), MDT: 71.34 (-0.65), SLXP: 110.11 (+7.08), SNY: 45.38 (+0.98)

Salix, Skyworks Lead 6 IBD50 EarningsReports On Tap
at Investor's Business Daily - Tue Nov 04, 7:02AM CST
Earnings season continues to barrel forward, and investors are anticipating results from several top drugmakers this upcoming week. This week's IBD 50, a roundup of top-rated growth stocks with solid fundamentals, boasts six companies reporting...
DRTX: 24.16 (+0.41), AGN: 205.75 (-3.26), ACT: 256.52 (-6.48), SWKS: 68.12 (-0.39), AKRX: 37.55 (-2.17), JAZZ: 159.65 (-2.95), SLXP: 110.11 (+7.08), AAPL: 106.75 (-1.47), ATHM: 36.50 (-1.54)

Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata
PR Newswire - Fri Oct 31, 3:15PM CDT
Actavis plc (NYSE: ACT) and Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR" with respect to Actavis' pending acquisition of Durata.
DRTX: 24.16 (+0.41), ACT: 256.52 (-6.48)

SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection With the Sale of Durata Therapeutics, Inc. -- DRTX
GlobeNewswire - Wed Oct 29, 1:02PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Illinois Circuit Court on behalf of all common stockholders of Durata Therapeutics, Inc. ("Durata" or the "Company" (Nasdaq RTX) opposing the proposed acquisition of Durata by Actavis plc ("Actavis" .
DRTX: 24.16 (+0.41)

INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Durata Therapeutics Inc. Concerning the Fairness of the Sale of the Company to Actavis
Business Wire - Tue Oct 14, 11:37AM CDT
Levi & Korsinsky is investigating the Board of Directors of Durata Therapeutics Inc. ("Durata" or "the Company" (NASDAQ: DRTX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Actavis (NYSE:ACT).
DRTX: 24.16 (+0.41), ACT: 256.52 (-6.48)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Durata Therapeutics, Inc. in Connection with the Sale of the Company
Business Wire - Sat Oct 11, 6:05AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Durata Therapeutics, Inc. ("Durata" or the "Company" (Nasdaq: DRTX) relating to the proposed acquisition by Actavis plc.
DRTX: 24.16 (+0.41)

DURATA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Durata Therapeutics Inc. (DRTX) Over the Proposed Sale of the Company to Actavis plc (ACT)
PR Newswire - Fri Oct 10, 5:45PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Durata Therapeutics Inc. ("Durata" or the "Company" (NasdaqGM: DRTX) for potential breaches of fiduciary duties in connection with the sale of the Company to Actavis plc for approximately $675 million. The Company's stockholders will only receive $23.00 for each share of Durata common stock they own, when according to Yahoo! Finance at least one analyst has set a price target of $26.00 for the Company. The deal price might be $5.00 higher based on a contingency-milestone basis.
DRTX: 24.16 (+0.41)

DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Fri Oct 10, 4:31PM CDT
Rigrodsky & Long, P.A.:
DRTX: 24.16 (+0.41), ACT: 256.52 (-6.48)

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Durata Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Fri Oct 10, 4:25PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Durata Therapeutics, Inc. (NASDAQ: DRTX), ("Durata" or the "Company" relating to the proposed buyout of the Company by Actavis plc ("Actavis" .
DRTX: 24.16 (+0.41)

Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014(TM)
GlobeNewswire - Fri Oct 10, 1:04PM CDT
Durata Therapeutics (Nasdaq RTX) today announced a summary of presentation data from its recently launched product, DALVANCE(TM) (dalbavancin) for injection. The data were presented in five posters at IDWeek 2014, which took place from October 8-11, 2014 in Philadelphia, PA. Among the findings, a study of pharmacokinetic activity in bone and associated tissues demonstrated that dalbavancin accumulates in bone and supports further study in patients with osteomyelitis and prosthetic joint infections. A separate analysis showed patients with ABSSSI who were treated with dalbavancin had similar clinical success rates to those treated with IV vancomycin alone, as well as a tendency to have fewer adverse events and less nephrotoxicity compared to patients who received IV vancomycin for greater-than or equal to10 days. An examination of ASO and DNase-B titers in patients with streptococcal skin infections in the dalbavancin DISCOVER program was also presented.
DRTX: 24.16 (+0.41)

Actavis plc and Valeant Pharmaceuticals Inc. Battle for Allergan Inc.: Who Wins?
George Budwell, The Motley Fool - Motley Fool - Thu Oct 09, 2:52PM CDT
Healthcare companies have been completing merger and acquisitions this year at record pace to counter  ongoing patent cliff troubles, as well as political gridlock in the U.S. over corporate tax reform.  Activist investor Bill Ackman and his hedge...
DRTX: 24.16 (+0.41), AGN: 205.75 (-3.26), VRX: 136.92 (-1.24), ACT: 256.52 (-6.48), SLXP: 110.11 (+7.08)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 112

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 160

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 135

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 157

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 142

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 118

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 111

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 97

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 94

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading

Top 5 Most Recently Viewed Articles

Health-Ade Partners with Wheel of Fortune and Ryan Seacrest

Updated Category News Views 212

Health-Ade Shines at Wheel of Fortune Premiere Health-Ade is thrilled to announce its prominent involvement in the premiere week of the classic game show, Wheel of Fortune, as it embarks on an exciting new journey with Ryan Seacrest as the show's host. This is an exhilarating moment not only for Wheel of Fortune but also for Health-Ade Kombucha, which is celebrated for...

Continue Reading
Investment Fund Trends and Insights for October 2024

Updated Category News Views 101

Mutual Fund and ETF Asset Management In the scope of mutual funds and exchange-traded funds (ETFs), the latest insights reveal a steady growth in assets and sales throughout the investment landscape. As investors look for diverse options, investment funds have shown resilience and dynamic adaptability, showcasing robust growth metrics in their respective categories....

Continue Reading
S&P and Pantera Take Digital Asset Indexing to New Heights

Updated Category News Views 18

Digital Assets: A New Benchmark in Town Date it, folks: July 21, 2026. S&P Dow Jones Indices and Pantera Capital are rolling out a fresh digital asset index. They're slapping the 'S&P Pantera' name on something focused less on the casino vibe you get from memes and Bitcoin mania, and more on actual economic value and real-world use. Flipping the script on the way most of...

Continue Reading
Gundry MD Wins Big with Innovative Softgel Formula

Updated Category News Views 57

Breaking New Ground in Weight Management Forget the caffeine-laden pills and appetite-killer potions—here comes something that simply whispers to your gut and says, "Manage your weight naturally." That's what Gundry MD's Daily Weight Advantage™ has cooked up, bagging the prestigious NutraIngredients-USA's Weight Management Product of 2026 award. Finally, a product...

Continue Reading
Ciena's Options Market Insights: Bullish Trends and Growth Prospects

Updated Category News Views 202

Understanding Ciena's Recent Options Activity Investors with significant resources have shown a clear bullish sentiment towards Ciena (NYSE: CIEN), indicating crucial trends that market observers should consider. By monitoring options records, it’s clear that substantial movements are occurring within the CIEN stock, hinting that noteworthy developments might be on the...

Continue Reading